Ariel Beresniak

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Ariel Beresniak
BERESNIAK Ariel b.jpg
Born (1961-12-03) 3 December 1961 (age 57)
Paris, France
Known forDeveloping innovative approaches in Health technology assessment
Scientific career
FieldsPublic Health, Health Economics
InstitutionsData Mining International Paris Descartes University

Ariel Beresniak (born 3 December 1961) is a Swiss specialist in Public Health and Health Economics, author of reference books and scientific articles in modeling and decision-making analyses.


Beresniak is a physician specialized in Public Health from the Faculty of Medicine at University of Marseille, France .[1] He also obtained a master's degree in Economics and a PhD in applied mathematics in Economics at the Claude-Bernard University (France), and an Accreditation to Supervise Research (Habilitation a Diriger des Recherches).[2] Beresniak was Head of Health Economics for Glaxo-Wellcome (1993-1999) and Global Head of Pharmacoeconomics for Serono International (1999-2004).[3] Since 2005, Beresniak is CEO of Data Mining International. He has been short-term consultant for the World Health Organization and the European commission in the fields of Public health and Health Economics.

Scientific contribution[edit]

Beresniak is author of the reference book "Health Economics" published in French and Portuguese.[4][5] He publishes two dictionaries: one dictionary of Health Economics published in French and Spanish, and one dictionary of terms used in health industries published in French.[6][7] Beresniak is also coauthor of "Understanding Pharmacoeconomics" published in French and "Pharmacoeconomics" published in Japanese.[8][9] Beresniak is known to have led the ECHOUTCOME project, a European Commission funded research, establishing that the QALY indicator (Quality Adjusted Life Years) is not scientifically validated to be used in Decision making and could lead to divergent results with the same dataset.[10] These findings have generated an international controversy because the QALY indicator is still currently promoted as reference case by some national health technology assessment agencies such as the NICE (National Institute for Health and Care Excellence) in the UK.[11][12][13] Beresniak is also project leader of the FLURESP project, a European Commission funded research, with the objective to compare cost-effectiveness of various public health interventions against human pandemic influenza.


  1. ^
  2. ^
  3. ^ A Beresniak, F Taboulet, Comprendre la Pharmacoéconomie, John Libbey Eurotext, 1996:125 p ISBN 2742001441
  4. ^ A Beresniak, G Duru, Economie de la santé, 6ième édition, Coll. des abrégés de médecine - MASSON 2007:180 p ISBN 9782294088506
  5. ^ A. Beresniak, G. Duru, Economia da Saude, Climepsi editors 1999:162 p ISBN 9728449143
  6. ^ JP Auray, A Beresniak, JP Claveranne, G Duru, Dictionnaire commenté d’Economie de la santé, Coll. des abrégés de médecine -Edition MASSON 1996: 289 p ISBN 9782225852848
  7. ^ JP Auray, A Beresniak, JP Claveranne, G Duru, Diccionario comentado de Economia de la salud, Editorial MASSON-Barcelona 1998: 351p ISBN 9788445805978
  8. ^ A Beresniak, F Taboulet, Comprendre la Pharmacoéconomie, John Libbey Eurotext, 1996:125 p ISBN 2742001441
  9. ^ K Tsutani, A Beresniak, 薬剤経済学の活用 医薬品の経済的エビデンスをつくる・つかう, Elsevier Japan, 2008:144p ISBN 978486034-564-8
  10. ^ Orpha News, Interview with Ariel Beresniak, 16 March 2006,
  11. ^ BBC News, J Dreaper, Researchers claim NHS drug decisions are flawed, 24 Jan 2013,
  12. ^ Daily Mail, C Bates, Drug watchdog should scrap flawed system used to ration life-saving medicines, warn EU experts,25 Jan 2013,
  13. ^ Nature Medicine, D Holmes, Report triggers quibbles over QALYs, a staple of health metrics, , Vol 19, Numb 3, March 2013